Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Methodist Cardiovascular Surgery Associates

Bridget N. Fahy, MD, FACS

Dr. Bridget N. Fahy

 

Education - Bridget N. Fahy, M.D., F.A.C.S.


Medical School

  • University of California, Irvine, Irvine, CA

Residency

  • University of California, Davis Medical Center, Sacramento, CA

Fellowships

  • Memorial Sloan-Kettering Cancer Center, New York, NY

Areas of Research

  • Colorectal Cancer
  • Metastatic Cancer
  • Palliative surgical interventions
  • Advanced Malignancies

Biography - Bridget N. Fahy, M.D., F.A.C.S.


Dr. Fahy is a native of California who completed her undergraduate studies at the University of California, Los Angeles with a degree in Psychology. She spent the next several years as a research assistant in the VA West Los Angeles / UCLA Department of Neurology where she studied the effects of HIV on the nervous system. During this time, she received a grant from the UCLA Psychoneuroimmunology Department to study the effect of coping, social support and mood on markers of HIV-1 infection. This early clinical research experience provided the impetus for her to pursue a career in medicine and she completed her medical studies at the University of California, Irvine in 1997. She received her general surgery training at the University of California, Davis. It was during this phase of her training that she started her oncology based research by studying the control of apoptosis in pancreatic cancer. At the completion of her general surgery training, she was accepted into the Surgical Oncology training program at the Memorial Sloan-Kettering Cancer Center. Her training at Memorial Sloan-Kettering included both general surgical oncology as well as focused training in colorectal oncology. She joined the faculty of The Methodist Hospital Department of Surgery in August 2006 and has several areas of research interest, including functional and quality of life outcomes following colorectal cancer treatment, chemotherapy-associated liver injury, surgical resection of metastatic disease, and enhanced lymph node staging in rectal cancer after neoadjuvant treatment.

Publications - Bridget N. Fahy, M.D., F.A.C.S.
  1. Aloia TA, Fahy BN. Chemotherapy-associated hepatotoxicity: How concerned should we be? Expert Rev Anticancer Ther. 2010 10(4):521-527.
  2. Fahy BN, Aloia TA, Jones SL, Bass BL, Fischer CP. Chemotherapy within 30 Days Prior to Liver Resection Does Not Increase Postoperative Morbidity or Mortality. HPB 2009 11:645-655.
  3. Jhaveri PM, Teh BS, Paulino AC, Smiedala MJ, Fahy B, Grant W, McGary J, Butler EB. Helical Tomotherapy Significantly Reduces Dose to Normal Tissues When Compared to 3D-CRT for Locally Advanced Rectal Cancer. Technol Cancer Res Treat. 2009 Oct;8(5):379-86.
  4. Aloia TA, Fahy BN, Fischer CP, Jones SL, Duchini A, Galati J, Gaber AO, Bass BL, Ghobrial RM. Predicting Poor Outcome Following Hepatectomy: Analysis of 2,313 Hepatectomies in the NSQIP Database. HPB. 2009 11(6):510-515.
  5. Aloia TA, Fahy BN. Chemotherapy-Associated Liver Injury: Does it Really Matter? Current Colorectal Cancer Reports. 2009 5:108-113.